Navigation Links
Roche Completes Acquisition of Genentech
Date:3/26/2009

BASEL, Switzerland and SAN FRANCISCO, March 26 /PRNewswire-FirstCall/ -- Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) and Genentech (NYSE: DNA) announced today that Roche has completed its acquisition of Genentech pursuant to a short-form merger in which Genentech became a wholly-owned member of the Roche Group. Roche had announced earlier in the day the successful completion of its tender offer, which expired on Wednesday, March 25. In connection with the merger, all remaining public shareholders will, subject to appraisal rights, receive $95.00 per share for their shares.

Genentech's common stock will no longer be traded on the New York Stock Exchange after Thursday, March 26.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2008 sales by the Pharmaceuticals Division totaled 36.0 billion Swiss francs, and the Diagnostics Division posted sales of 9.7 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interest in Chugai, and invested nearly 9 billion Swiss francs in R&D in 2008. Worldwide, the Group employs about 80,000 people. Additional information is available on the Internet at www.roche.com.

About Genentech

Founded more than 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with significant unmet medical needs. The company has headquarters in South San Francisco, California and is listed on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit http://www.gene.com.

    Roche Group Media Relations
    Phone: +41 61 688 8888 / e-mail: basel.mediaoffice@roche.com
    - Daniel Piller (Head)
    - Alexander Klauser
    - Martina Rupp
    - Claudia Schmitt

    Brunswick Group (for US media)
    Phone: +1 212 333 3810
    - Jennifer Lowney

    Genentech
    Media Contact
    Phone: +1 650 225 8171
    - Geoffrey Teeter

    Investor Contact
    Phone: +1 650 225 1034
    - Kathee Littrell


'/>"/>
SOURCE Roche
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. The College of New Rochelle School of Nursing Receives $50,000 Grant From the Verizon Foundation for Telenursing Pilot Program
2. Roche Increases Offer Price for Genentech Shares to US$ 93.00 per Share and Extends Offer
3. Rochester Medical Renews Share Repurchase Activity
4. Access Pharmaceuticals Closes Acquisition of MacroChem Corp.
5. University of Rochester Launches iTraining for Emergency Responders
6. Roche Announces Significant Price Reduction of Two ACCU-CHEK(R) Glucose Monitoring Kits to Help Customers With Diabetes During These Difficult Economic Times
7. Rochester Medical Reports First Quarter Results
8. Rochester study raises new questions about controversial plastics chemical
9. University Medical Pharmaceuticals Appoints Tom Roche as Senior Vice President, Global Sales and Marketing
10. Rochester Medical Announces First Quarter 2009 Earnings Conference Call February 2, 2009
11. Rochester Medical Announces Settlement With TYCO Healthcare Group, L.P., Now Operating as Covidien Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... Hospital M&A activity slowed in the ... number of hospital acquisitions rose to 23 in the second quarter, up 15% from ... from the 20 announced deals in the year-ago second quarter. Only four of the ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... a $5,000 grant from the C. R. Bard Foundation, Inc. to ... Somerset Hills , a service available through the nonprofit home care agency. Using ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased to ... PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network of ... in dermatology, skin cancer , and more. She graduated from the University of ...
(Date:7/20/2017)... ... July 20, 2017 , ... TransPixel Volume 2 is a set of transitions ... timeline. This effect isolates horizontal and vertical lines of pixels and sorts their pixels ... or flipping animation and can be changed using a drop-down menu. Create amazing and ...
(Date:7/20/2017)... Houston, Texas (PRWEB) , ... July 20, 2017 ... ... and litigation law firm headquartered in Houston, is pleased to announce their expansion ... decades of affordable housing experience, directors Alysse Hollis and Ronald Bell, and of ...
Breaking Medicine News(10 mins):
(Date:7/14/2017)... -- Endo International plc (NASDAQ: ENDP ) will announce ... of its senior management team will host a conference call and ... The dial-in number to access the call is ... the passcode is 45397076. Please dial in 10 minutes prior to ... A replay of the call will be available from August 8, ...
(Date:7/13/2017)... 13, 2017  New York City-based market research firm Kalorama ... be aware of.  From new products to new costs, to ... a recently completed study, Potential Pipeline Disruptors . ... 1.  Age-Driven Growth - True Impact Moment ... of the impact the growing population and, to a more ...
(Date:7/11/2017)... WHIPPANY, N.J. , July 11, 2017  Bayer has ... across eight countries as part of its prestigious Bayer Hemophilia ... Children,s Hospital of Philadelphia and Uniformed ... are among the winners. Grant recipients were announced ... Thrombosis and Hemostasis (ISTH) 2017 Congress, Berlin, Germany ...
Breaking Medicine Technology: